Teva Pharmaceutical Industries Ltd. (TEVA) said the U.S. Food and Drug Administration approved AirDuo Digihaler Inhalation Powder.
That is a combination therapy digital inhaler with built-in sensors that connects to a companion mobile application for information on inhaler use to people with asthma.
AirDuo Digihaler is indicated for the treatment of asthma in patients aged 12 and older.
The approval of AirDuo Digihaler is based on the review of the supplemental new drug application Teva submitted to the FDA.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.